Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)

Summary

Recombinant growth hormone (rhGH) treatment is widely used in France to normalize height during childhood and final height in children born small for gestational age (SGA). Because rhGH has been associated with increased insulin levels and insulin resistance, concern has been expressed regarding the late consequences of rhGH treatment on risk factors for diabetes mellitus type II and metabolic syndrome, especially in possibly predisposed subjects as SGA children.

Timeline

Start

2008-01

Primary completion

2012-01

Completion

2012-01

Outcome

Outcome not reported

Stopped: “no more inclusions”

Drugs

Indications